NUFORMIX PLC

Capital/Financing Update • Dec 18, 2023

National Storage Mechanism | Additional information

RNS Number : 0704X

Nuformix PLC

18 December 2023

18 December 2023

Nuformix plc

("Nuformix" or the "Company")

NXP001 Update

Nuformix receives second NXP001 milestone payment from Oxilio

​

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio Ltd ("Oxilio") and received the associated payment.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "Oxilio is progressing NXP001 with Nuformix's full support. We are pleased to have triggered the second milestone payment as per the terms of our updated agreement. Funds received continue to assist in advancing our core NXP002 and NXP004 programmes as we progress partnering interactions for these programmes."

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
Bob Pountney (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFDLLFXLLFFBZ